This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AET, EVHC, HCA Q3 Earnings: Here are the Key Predictions
by Zacks Equity Research
Third-quarter results of the Healthcare stocks are likely to be impacted by the noise around Affordable Care Act, industry-wide softness in volume, rising level of bad debt and higher expenses.
Will High Costs Dent Envision Healthcare (EVHC) Q3 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) third-quarter earnings are likely to see a drag from high expenses, partly offset by increased revenues from its physician services segment.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
Will Higher Admissions Aid HCA Healthcare (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter earnings are likely to be benefited by its inorganic growth measures partly offset by industry weakness.
Is a CVS Health (CVS) - Aetna (AET) Deal in the Cards?
by Arpita Dutt
Is an e-commerce company's interest in entering the drug pharmacy space the reason behind CVS Health's (CVS) interest in acquiring Aetna?
Strength Seen in Aetna (AET): Stock Soars 11.5%
by Zacks Equity Research
Aetna (AET) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Why Earnings Season Could Be Great for Aetna (AET)
by Zacks Equity Research
Aetna (AET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
Anthem (ANTM) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Anthem, Inc. (ANTM) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.
Merck vs. Pfizer: Which is Better Ahead of Q3 Earnings?
by Swarup Gupta
With Merck and Pfizer scheduled to report on Oct 27 and Oct 31, respectively this may be a good time to consider which of these is a better stock.
Can Admissions Rise Fuel Universal Health (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) third-quarter results are likely to be driven by solid revenue growth in both its Acute Care and Behavioral Health segments.
Can Enrollment Growth Drive Anthem (ANTM) in Q3 Earnings?
by Zacks Equity Research
Anthem's (ANTM) third-quarter results are likely to be aided by membership growth.
Can Medicaid Business Drive Centene's (CNC) Q3 Earnings?
by Zacks Equity Research
Centene's (CNC) third-quarter results are expected to be positively impacted by its Medicaid expansion initiatives.
UnitedHealth (UNH) Beats Q3 Earnings on Higher Membership
by Zacks Equity Research
UnitedHealth (UNH) beats earnings in the third quarter driven by higher contribution from both its segments.
Health Care Stocks Stumble on Trump's Executive Order
by Zacks Equity Research
Trump's executive order has sent jitters across the hospital sector that has been weighed down by a weak business environment also insurers remain unsure.
Anthem (ANTM) & Units Receive Medicare Star Ratings From CMS
by Zacks Equity Research
Anthem's (ANTM) focus on improving the quality of healthcare for its Medicare Advantage members has enabled it achieve favorable Star Ratings from CMS
UnitedHealth (UNH) Q3 Earnings Likely to Beat: Here's Why?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter earnings are expected to benefit from strong contribution from both its segments along earnings accretion from disciplined capital management.
WellCare Partners UNC to Boost Medicare in North Carolina
by Zacks Equity Research
WellCare (WCG) has been building partnerships in order to expand its geographical presence and improve the quality of its offerings.
Anthem Grows on Membership, Public Exchange Woes Hurt
by Zacks Equity Research
Although Anthem's (ANTM) revenue base continues to strengthen on the back of growing membership. Losses incurred in the public exchange business bother.
3 Stocks from Wall Street's Hottest Industries to Buy Now
by Benjamin Rains
There are many different ways to make money in the stock market. One proven way to earn great returns, which many investors use, is to invest in stocks within the best performing industries.
Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.
Stock Market News For Sep 25, 2017
by Zacks Equity Research
Markets closed slightly higher on Friday after healthcare stocks surged after Senator McCain decided not to support the repealing of the Affordable Care Act.
Anthem to Boost Medicare in Florida With HealthSun Buyout
by Zacks Equity Research
Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.
Is Aetna Inc. (AET) a Great Stock for Value Investors?
by Zacks Equity Research
Is Aetna Inc. (AET) a great pick from the value investor's perspective right now? Read on to know more.
Health Care Stocks in Focus as Repeal & Replace Gains Steam
by Zacks Equity Research
Healthcare stocks are jittery due to the regulatory uncertainty that the Graham-Cassidy bill may bring along.